Jazz Pharmaceuticals plc
JAZZJazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Drugs in Pipeline
50
Phase 3 Programs
28
Upcoming Catalysts
5
Next Catalyst
This month
Market Overview
Stock performance and key metrics
6 upcoming, 0 past
How JAZZ's past catalysts played out
GW-2000-02
Pain
Nabiximols
Pain
JZP-110
Obstructive Sleep Apnea
Brincidofovir
Adenovirus Infection
Xyrem®
Fibromyalgia
Dordaviprone (ONC201)
H3 K27M
Sodium Oxybate
Essential Tremor
IM JZP-458
Acute Lymphoblastic Leukemia
GW-1000-02
Pain
Modafinil at established dose
Narcolepsy
Sodium Oxybate & 6 Tablets
Fibromyalgia
Zanidatamab
HER2-positive Breast Cancer
Gemcitabine
Metastatic HER2-positive Breast Cancer
Capecitabine
Gastric Neoplasms
CPX-351
Acute Myeloid Leukemia (AML)
Pembrolizumab
Biliary Tract Cancer
7+3 (cytarabine and daunorubicin)
High Risk Acute Myeloid Leukemia
Defibrotide
Severe Hepatic Veno-Occlusive Disease
experimental anti-anxiety drug
Anxiety Disorder
Sativex
Multiple Sclerosis
Xyrem (sodium oxybate) oral solution
Fibromyalgia
a benzodiazepine drug
Anxiety Disorder
JZP-258
Idiopathic Hypersomnia
THC Alone
Palliative Care
Sativex®
Spasticity
GWP42003-P
Epilepsy
GWP42003-P 20 mg/kg/day Dose
Epilepsy
Xyrem
Narcolepsy With Cataplexy
Suvecaltamide
Parkinson Disease
asparaginase Erwinia chrysanthemi
Acute Lymphoblastic Leukemia
ADX-N05
Narcolepsy
Daunorubicin
Acute Myeloid Leukemia
Clobazam
Epilepsy
Lurbinectedin
Refractory Ewing Sarcoma
GWP42006
Epilepsy
ZW25 (Zanidatamab)
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
GWP42003
Schizophrenia
Evorpacept
HER2-expressing Cancers
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Colorectal Neoplasms
CX-8998
Epilepsy
GWP42004
Dyslipidemias
JZP150
Post Traumatic Stress Disorder
JZP385
Essential Tremor
Clonazepam
Epilepsy
GWP42003-P 5 mg/kg/day Dose
Epilepsy
Standard of Care
Graft-versus-host Disease
Intensive Salvage Therapy
Acute Myeloid Leukemia
ONC206
Advanced Pheochromocytoma and Paraganglioma
Palbociclib
HER2+/HR+ Breast Cancer
Dociparstat sodium
Acute Myeloid Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GW-2000-02 | Phase 3 | Pain | - | - |
Nabiximols | Phase 3 | Pain | - | - |
JZP-110 | Phase 3 | Obstructive Sleep Apnea | - | - |
Brincidofovir | Phase 3 | Adenovirus Infection | - | - |
Xyrem® | Phase 3 | Fibromyalgia | - | - |
Dordaviprone (ONC201) | Phase 3 | H3 K27M | - | - |
Sodium Oxybate | Phase 3 | Essential Tremor | - | - |
IM JZP-458 | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
GW-1000-02 | Phase 3 | Pain | - | - |
Modafinil at established dose | Phase 3 | Narcolepsy | - | - |
Sodium Oxybate & 6 Tablets | Phase 3 | Fibromyalgia | - | - |
Zanidatamab | Phase 3 | HER2-positive Breast Cancer | - | - |
Gemcitabine | Phase 3 | Metastatic HER2-positive Breast Cancer | - | - |
Capecitabine | Phase 3 | Gastric Neoplasms | - | - |
CPX-351 | Phase 3 | Acute Myeloid Leukemia (AML) | - | - |
Pembrolizumab | Phase 3 | Biliary Tract Cancer | - | - |
7+3 (cytarabine and daunorubicin) | Phase 3 | High Risk Acute Myeloid Leukemia | - | - |
Defibrotide | Phase 3 | Severe Hepatic Veno-Occlusive Disease | - | - |
experimental anti-anxiety drug | Phase 3 | Anxiety Disorder | - | - |
Sativex | Phase 3 | Multiple Sclerosis | - | - |
Xyrem (sodium oxybate) oral solution | Phase 3 | Fibromyalgia | - | - |
a benzodiazepine drug | Phase 3 | Anxiety Disorder | - | - |
JZP-258 | Phase 3 | Idiopathic Hypersomnia | - | - |
THC Alone | Phase 3 | Palliative Care | - | - |
Sativex® | Phase 3 | Spasticity | - | - |
GWP42003-P | Phase 3 | Epilepsy | - | - |
GWP42003-P 20 mg/kg/day Dose | Phase 3 | Epilepsy | - | - |
Xyrem | Phase 3 | Narcolepsy With Cataplexy | - | - |
Suvecaltamide | Phase 2 | Parkinson Disease | - | - |
asparaginase Erwinia chrysanthemi | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
ADX-N05 | Phase 2 | Narcolepsy | - | - |
Daunorubicin | Phase 2 | Acute Myeloid Leukemia | - | - |
Clobazam | Phase 2 | Epilepsy | - | - |
Lurbinectedin | Phase 2 | Refractory Ewing Sarcoma | - | - |
GWP42006 | Phase 2 | Epilepsy | - | - |
ZW25 (Zanidatamab) | Phase 2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | - | - |
GWP42003 | Phase 2 | Schizophrenia | - | - |
Evorpacept | Phase 2 | HER2-expressing Cancers | - | - |
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection | Phase 2 | Colorectal Neoplasms | - | - |
CX-8998 | Phase 2 | Epilepsy | - | - |
GWP42004 | Phase 2 | Dyslipidemias | - | - |
JZP150 | Phase 2 | Post Traumatic Stress Disorder | - | - |
JZP385 | Phase 2 | Essential Tremor | - | - |
Clonazepam | Phase 2 | Epilepsy | - | - |
GWP42003-P 5 mg/kg/day Dose | Phase 2 | Epilepsy | - | - |
Standard of Care | Phase 2 | Graft-versus-host Disease | - | - |
Intensive Salvage Therapy | Phase 2 | Acute Myeloid Leukemia | - | - |
ONC206 | Phase 2 | Advanced Pheochromocytoma and Paraganglioma | - | - |
Palbociclib | Phase 2 | HER2+/HR+ Breast Cancer | - | - |
Dociparstat sodium | Phase 2 | Acute Myeloid Leukemia | - | - |
Epilepsy
2 drugs in this indication
Pain
1 drug in this indication
Parkinson Disease
1 drug in this indication
Multiple Sclerosis
1 drug in this indication
Spasticity
1 drug in this indication
Narcolepsy With Cataplexy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Jazz Pharmaceuticals plc's drug pipeline?→
CatalystAlert tracks 50 drug candidates in Jazz Pharmaceuticals plc's (JAZZ) pipeline across Phase 3, Phase 2. Its lead program is GW-2000-02 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Jazz Pharmaceuticals plc's next FDA catalyst?→
Jazz Pharmaceuticals plc's (JAZZ) next tracked catalyst is a Phase 3 expected July 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JAZZ biotech catalysts?→
Add JAZZ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Jazz Pharmaceuticals plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.